Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
评估 DS-1205c(一种 AXL 激酶抑制剂)联合奥希替尼治疗转移性或不可切除的 EGFR 突变型非小细胞肺癌的疗效:一项多中心、开放标签的 1 期研究结果
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-023-01341-y
Yang, James Chih-Hsin; Su, Wu-Chou; Chiu, Chao-Hua; Shiah, Her-Shyong; Lee, Kang-Yun; Hsia, Te-Chun; Uno, Makiko; Crawford, Nigel; Terakawa, Hiroshi; Chen, Wen-Chi; Takayama, Gensuke; Hsu, Ching; Hong, Ying; Saintilien, Carline; McGill, Joseph; Chang, Gee-Chen
肺癌
肿瘤
肿瘤免疫
信号转导
EGF
AXL
EGFR
细胞生物学